Streetbeat News

Earnings

ARKR

Ark Restaurants (NASDAQ:ARKR) reported a significant decrease in Q3 earnings per share (EPS) to $0.18, down 79.55% from $0.88 YoY. Sales also declined slightly to $50.40 million, a 1.28% decrease from $51.05 million YoY.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:26 pm

KYTX

Kyverna Therapeutics (NASDAQ:KYTX) reported a Q2 EPS of $(0.67), missing the analyst consensus estimate of $(0.64) by 4.69%.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:25 pm

DARE

Dare Bioscience shares are trading higher following the company's Q2 financial results announcement.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:25 pm

CATX

Perspective Therapeutics shares are trading lower following the company's Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:24 pm

KULR

KULR Tech Group (AMEX:KULR) reported Q2 2024 GAAP EPS of $(0.03), which met analyst expectations. The company achieved sales of $2.432 million, surpassing the $2.228 million estimate but reflecting a 9.79% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:24 pm

DDI

DoubleDown Interactive shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:24 pm

GETR

Getaround (NYSE:GETR) reported Q2 2024 GAAP EPS of $(0.12), beating the $(0.18) estimate, but sales of $18.584M missed the $19.520M estimate. Sales decreased by 0.19% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:24 pm

BZFD

BuzzFeed expects Q3 overall revenues to be between $58 million and $63 million, with adjusted EBITDA ranging from $6 million to $11 million.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:23 pm

CATX

Perspective Therapeutics (AMEX:CATX) reported Q2 EPS of $(0.17), beating the $(0.21) estimate, and sales of $526K, surpassing the $60K estimate. Despite a 50% improvement in EPS from last year, sales decreased by 10.54% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:23 pm

SRZN

Surrozen (NASDAQ:SRZN) reported a Q2 2024 adjusted EPS of $(7.99), significantly missing the analyst consensus estimate of $(2.79) by 186.38%.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:22 pm